|1.||Guillevin, Loïc: 17 articles (08/2015 - 04/2003)|
|2.||Pagnoux, Christian: 14 articles (08/2015 - 04/2003)|
|3.||Cacoub, Patrice: 9 articles (12/2015 - 12/2007)|
|4.||Shoenfeld, Yehuda: 9 articles (09/2013 - 11/2002)|
|5.||Beaugerie, Laurent: 8 articles (09/2015 - 01/2004)|
|6.||Sandborn, William J: 8 articles (09/2014 - 05/2004)|
|7.||Guillevin, L: 7 articles (05/2014 - 12/2000)|
|8.||Mouthon, Luc: 7 articles (01/2012 - 06/2005)|
|9.||Saadoun, David: 6 articles (09/2015 - 11/2009)|
|10.||Peyrin-Biroulet, Laurent: 6 articles (09/2014 - 07/2013)|
06/01/1999 - "Data from Phase III clinical trials of new immunosuppressants, however, show a statistically significant reduction in the incidence of acute rejection produced by these new drugs, which has not been accompanied by increases in infection and malignancy rates. "
01/01/2002 - "Significant advances over the past 20 years in surgical technique, immunosuppressive agents, patient selection, and infection prophylaxis and treatment have led to improved patient and graft survival. "
10/01/1989 - "With a better understanding of the pathogenesis of infection in the transplanted lung as well as improved immunosuppressive agents, further improvements in survival can be expected."
11/01/2008 - "Administration of immunosuppressants was effective in cases with autoimmune-associated HPS, whereas prognosis was poor in infection-associated HPS."
05/01/2011 - "Improved outcomes using anti-inflammatory/immunosuppressive agents do not rule out infection as a driver for autoimmunity. "
03/01/1996 - "Low-dose CSA used alone or in combination with other immunosuppressive agents is effective in achieving inflammatory control with a favorable visual outcome and provides a useful steroid-sparing strategy in the management of chronic endogenous uveitis. "
06/01/2009 - "MMF was safe and effective in controlling CMO and in reducing the uveitis relapse rate in patients not responding to traditional immunosuppressants. "
01/01/2014 - "We also discuss the stepwise approach to medical treatment of immune-mediated uveitis as well as the characteristics, safety, and efficacy of immunosuppressive agents used to treat ocular inflammatory disease. "
03/01/2013 - "This review describes the clinical studies and adverse effects of TNF-α blockers in the treatment of uveitis, and discusses the principle for clinical use of TNF-α blockers in synergy with other immunosuppressive agents."
01/01/2013 - "The purpose of this study was to describe comorbidities, healthcare costs, and resource utilization among patients with chronic non-infectious uveitis initiating corticosteroid, immunosuppressants, or biologics.In"
12/01/2012 - "Moreover, the ongoing studies evaluating the efficacy of emerging immunosuppressants in treating patients with ulcerative colitis are discussed. "
01/01/2002 - "Do immunosuppressants really work as maintenance therapy after the achievement of remission of severe ulcerative colitis?"
09/01/2014 - "Although these immunosuppressants are known to effectively control ulcerative colitis (UC), some post-OLT patients develop exacerbation of preexisting UC or de novo UC. "
01/01/2012 - "When the patients are treated with immunosuppressants that make them more susceptible to CMV, the course of ulcerative colitis (UC) becomes considerably worse. "
09/01/2008 - "Some patients with ulcerative colitis (UC) require immunosuppressants as maintenance therapy. "
|4.||Pemphigus (Pemphigus Vulgaris)
01/01/2010 - "Thus, we may conclude that: (i) the percentage of patients with oropharyngeal pemphigus vulgaris who achieved complete long-lasting clinical remission was very high; (ii) transient lesions that healed within a week were very frequent and had to be actively controlled; (iii) if treated early, most patients had a good clinical response and could achieve a disease- and drug-free clinical remission; (iv) early treatment may prevent extension or progression of disease; (v) there is a possible role for immunosuppressive agents; and (vi) a more favorable course of the disease, in terms of attainment and duration of clinical remission and a better prognosis, seemed to be related to a rapid response to therapy rather than to the initial severity and extent of the disease."
11/01/2003 - "For the treatment of pemphigus, a course of the lowest possible corticosteroid dosage in combination with immunosuppressive agents appears to be effective and less toxic than a high corticosteroid dosage."
11/01/2002 - "Although pemphigus vulgaris is still a life-threatening disease, today it can be successfully treated with a combination of immunosuppressive agents. "
10/12/2015 - "Eliminating possible drug PV/PF triggers/sustainers may alleviate the clinical symptoms and enable the decrease of dose/range of immunosuppressants regardless of pemphigus form."
10/12/2015 - "Drug triggering should be suspected in every case of newly diagnosed or exacerbated pemphigus, as eliminating possible PV/PF triggers/sustainers may alleviate the clinical symptoms and enable the decrease of dose/range of immunosuppressants regardless of pemphigus form. "
09/01/2011 - "A total of 294 of these patients were prospectively treated with renin-angiotensin system blockade and immunosuppressants sequentially and were evaluated separately to assess the predictive value to therapeutic efficacy (defined as time-averaged proteinuria <1 g/d). "
01/01/1995 - "Immunosuppressive agents may be efficient in some of steroid-resistant patients, inducing remission of proteinuria and protecting renal function. "
11/01/2015 - "At the end of the follow-up, 14 of the 17 patients treated with immunosuppressants and 10 of 11 patients on supportive therapy had a remission of proteinuria. "
08/01/2008 - "The other 44 children were nearly all in remission, 18 without treatment at follow-up, and the rest on various immunosuppressants, but one had persistent proteinuria and multiple segmental lesions. "
11/01/2013 - "Combination with immunosuppressive agents might be considered in cases of rapid renal function deterioration and/or severe proteinuria. "
|1.||Adrenal Cortex Hormones (Corticosteroids)
|9.||mycophenolate mofetil (Cellcept)
|2.||Transplantation (Transplant Recipients)